Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants

被引:48
|
作者
Barbaro, Danielle
Boni, Giuseppe
Meucci, Giuseppe
Simi, Umberto
Lapi, Paola
Orsini, Paola
Pasquini, Cristina
Turco, Anna
Mariani, Giuliano
机构
[1] Spedali Riuniti Livorno, Endocrinol Sect, I-57100 Livorno, Italy
[2] Univ Pisa, UO Nucl Med, Pisa, Italy
关键词
rhTSH; differentiated thyroid cancer; radiometabolic treatment;
D O I
10.1097/00006231-200608000-00005
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective To investigate whether recombinant human thyroid-stimulating factor (rhTSH) is effective for the radiometabolic ablation of post-surgery thyroid remnants, using low doses of I-131. Patients and methods The study included two groups of patients enrolled consecutively: group 1 consisted of 52 patients with papillary cancer or minimally invasive follicular cancer (stage I and 11), and group 2 consisted of 41 patients with the same stage of disease. All patients underwent a total thyroidectomy. Group 1 received 1.11 GBq (30 mCi) I-131 for post-surgical remnants ablation with the aid of rhTSH, while group 2, in the hypothyroid state, received the same amount of radioiodine. To minimize iodine interference, all patients remained on a low iodine diet for 2 weeks and L-thyroxine (L-T4) was stopped for 4 days in the group of patients treated with the aid of rhTSH. To investigate I-131 uptake in this group, a tracer dose was administered 3 h after the second injection of rhTSH and the uptake was evaluated at 24 h just before administration of the therapeutic dose. I-131 was also measured in the patients treated in the hypothyroid state just before the therapeutic dose was given. Results After 1 year both groups were studied by using whole-body scintigraphy (WBS) and measuring thyroglobulin after rhTSH. In group 1, WBS was negative in 76.9% (40 patients), while thyroglobulin-stimulated levels were < 1.0 ng(.)ml(-1) in 86.5% (45 patients). In Group 2, WBS was negative in 75.6% (31 patients), while thyroglobulin-stimulated levels were < 1 ng(.)ml(-1) in 78.0% (32 patients). I-131 uptake was 2.29 +/- 0.45 in the group treated with the aid of rhTSH, and 3.30 +/- 0.7 in the group treated in the hypothyroid state (P=0.2). No patients treated with the aid of rhTSH and with the short stoppage of L-T4 experienced symptoms of hypothyroidism, and free thyroxine (FT4) and thyroid-stimulating hormone levels remained normal. Conclusions Our data confirm that, when the interference of iodine is minimized, rhTSH is highly effective for the treatment of post-surgical thyroid remnants using a low dose of I-131.
引用
收藏
页码:627 / 632
页数:6
相关论文
共 50 条
  • [1] Recombinant Human Thyroid-Stimulating Hormone in Radioiodine Thyroid Remnant Ablation
    Mylonas, Chrystalleni
    Zwas, Shifra T.
    Rotenberg, Galina
    Omry, Gal
    Cohen, Ohad
    [J]. ISRAEL MEDICAL ASSOCIATION JOURNAL, 2014, 16 (02): : 106 - 109
  • [2] Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone
    Berg, G
    Lindstedt, G
    Suurküla, M
    Jansson, S
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2002, 25 (01) : 44 - 52
  • [3] Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone
    G. Berg
    G. Lindstedt
    M. Suurküla
    S. Jansson
    [J]. Journal of Endocrinological Investigation, 2002, 25 : 44 - 52
  • [4] Assessment of Variables Associated with the Post-surgical Radioiodine Ablation of Thyroid Remnants
    Akgun, A.
    Omur, O.
    Hatipoglu, F.
    Uz, H.
    Ozcan, Z.
    Ozkilic, H.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S410 - S411
  • [5] Radioiodine ablation of post-surgical thyroid remnants after preparation with recombinant human TSH: Why, how and when
    Barbaro, D.
    Boni, G.
    [J]. EJSO, 2007, 33 (05): : 535 - 540
  • [6] Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer in children, adolescents and young adults
    Schumm, Max A.
    Pyo, Howard Q.
    Kim, Jiyoon
    Tseng, Chi-Hong
    Yeh, Michael W.
    Leung, Angela M.
    Chiu, Harvey K.
    [J]. CLINICAL ENDOCRINOLOGY, 2021, 95 (02) : 344 - 353
  • [7] Cost-Effectiveness of Using Recombinant Human Thyroid-Stimulating Hormone before Radioiodine Ablation for Thyroid Cancer: The Canadian Perspective
    Mernagh, Paul
    Suebwongpat, Arsupol
    Silverberg, Jay
    Weston, Adele
    [J]. VALUE IN HEALTH, 2010, 13 (02) : 180 - 187
  • [8] Comparison of the biological activity of recombinant human thyroid-stimulating hormone with bovine thyroid-stimulating hormone and evaluation of recombinant human thyroid-stimulating hormone in healthy dogs of different breeds
    Boretti, FS
    Sieber-Ruckstuhl, NS
    Willi, B
    Lutz, H
    Hofmann-Lehmann, R
    Reusch, CE
    [J]. AMERICAN JOURNAL OF VETERINARY RESEARCH, 2006, 67 (07) : 1169 - 1172
  • [9] Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer treatment in Spanish hospitals
    Vallejo, J. A.
    Muros, M. A.
    [J]. REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2017, 36 (06): : 362 - 370
  • [10] Recombinant human thyroid-stimulating hormone as an alternative for thyroid hormone withdrawal in thyroid cancer management
    Chen, Ming-Kai
    Doddamane, Indukala
    Cheng, David W.
    [J]. CURRENT OPINION IN ONCOLOGY, 2010, 22 (01) : 6 - 10